<DOC>
	<DOCNO>NCT01120457</DOCNO>
	<brief_summary>The purpose study assess safety tolerability BMS-936564 ( MDX-1338 ) relapse Acute myelogenous leukemia ( AML ) select B-cell cancer determine maximum tolerate dose ( MTD ) drug alone relapsed/refractory AML</brief_summary>
	<brief_title>First Human Study Determine Safety , Tolerability Preliminary Efficacy Anti-CXCR4 Antibody Subjects With Acute Myelogenous Leukemia Selected B-cell Cancers</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . A . Common All Indications : Life expectancy least 12 week ECOG Performance Status 02 B . For Acute myelogenous leukemia ( AML ) Subjects : First Relapse primary induction failure AML ( M3 exclude ) Secondary AML subject myelodysplastic syndrome ( MDS ) prior chemotherapy eligible . MDSonly subject eligible C. For Follicular Lymphoma ( FL ) , Diffuse Large BCell Lymphoma ( DLBCL ) Subjects : Must least 4 week ( FL ) 2 week ( DLBCL ) since prior cytotoxic , biologic , monoclonal antibody , investigational therapy Ability undergo tumor biopsy pretreatment end monotherapy period ( though mandatory subject ) Subjects must histologically confirm diagnosis relapse refractory disease D. For Chronic lymphocytic leukemia ( CLL ) Subjects : Subjects must histologically confirm diagnosis relapse refractory disease Must least 4 week since prior cytotoxic , biologic , monoclonal antibody , investigational therapy , include corticosteroid A . Common All indication : Prior antiCXCR4 therapy include BMS936564 ( MDX1338 ) Less 3 month prior hematopoietic stem cell transplant Presence active graft versus host disease B . For AML Subjects : Acute promyelocytic leukemia ( M3 ) Left ventricular ejection fraction &lt; institutional limit normal C. For FL , DLBCL Subjects : ( For DLBCL ) : Inadequate renal function define creatinine clearance ( CockcroftGault formula ) &lt; 60 mL/min Major surgery , relate debulking procedure , within 21 day first dose Myocardial infarction within 6 month prior screen Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia Myelodysplastic syndrome ( MDS ) D. For CLL Subjects : No progression aggressive Bcell cancer , Richter 's syndrome Major surgery within 21 day Cycle 1 , Day 1 . Patients undergo debulking procedure minor surgery allow recovery period , judgment Investigator Myocardial infarction within 6 month prior screen Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>